
IMPACT THERAP-B
07630 · HKEXYingpai Pharmaceuticals is dedicated to tdevelopment of innovative, targeted anticproprietary intellectual property rights,focus on the synthetic lethality mechanis
IPO Timeline
- AbiertoMay 05
- CerrarMay 08
- SuscripciónMay 12
- PagoMay 13
- ListaMay 13
Principales hechos
Precio del número
HKD 20.10
Min Entry Fee
HKD 4,393.86
Acciones publicadas
41.98M
Tamaño del lote
200
Total Raise
HKD 843.7M
Estimación de la capacidad de mercado
—
Asignación pública
10.0%
International Placement
90.0%
Panorama general de las empresas
Yingpai Pharmaceuticals is dedicated to tdevelopment of innovative, targeted anticproprietary intellectual property rights,focus on the synthetic lethality mechanis
Uso de Proceeds
1、Approximately 51% or HK$398.37 million will be allocated to fund the ongoing and planned clinical development, regulatory approval and commercialization of the core product Senaparib;
2、Approximately 31% or HK$242.15 million will be used to finance the ongoing clinical development of key products IMP1734 and IMP9064;
3、Approximately 8% or HK$62.49 million will be allocated to the R&D activities of other pipeline assets, including IMP1707, IMP7068, IMP22, IMP25, IMP08, IMP13 and IMP10;
4、Approximately 8% or HK$62.49 million will be used for the development of R&D platforms and the expansion of the pharmaceutical pipeline;
5、Approximately 2% or HK$15.62 million will be applied to working capital and other general corporate purposes.
Patrocinio del registro de seguimiento
Intermediarios " Documentos "
Patrocinadores
- 高盛(亞洲)有限責任公司
- 中國國際金融香港證券有限公司
Underwriters
- 高盛(亞洲)有限責任公司
- 中國國際金融香港證券有限公司
- 招銀國際融資有限公司
- 老虎證券(香港)環球有限公司
Prospectus PDF
Prospectus PDF →Cornerstone Investors
- 南京生物医药谷建设发展有限公司及华泰资本投资
- 黄河投资有限公司
- 睿远基金
- First Quarter Moon OFC-Phecda Fund
- LAV Star Limited
- LAV Star Opportunities Limited
- Prosper High Holding Limited
- Worldwide Healthcare Partners LLC
Total
0
32.1% of placement
BBX no participa en el proceso de asignación para cualquier IPO enumerado en esta página. Esta página es sólo para fines informativos y no es asesoramiento de inversión.